Paradigm Biopharmaceuticals
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Paradigm Biopharmaceuticals sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Paradigm Biopharmaceuticals: 2 sponsored US clinical trials, 1 recruiting.
Paradigm Biopharmaceuticals sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Osteoarthritis, Knee, with 1 trials.
Mid-pack sponsor footprint
Paradigm Biopharmaceuticals is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
NCT06917404
Treatment and Duration Effect of Pentosan Polysulfate Sodium (PPS) in Participants With Knee Osteoarthritis Pain
NCT04814719
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Therapeutic Areas
Where Paradigm Biopharmaceuticals enrollment is open (later-stage tilt)
1 recruiting of 2 indexed (50% open); 1 completed (50%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Osteoarthritis, Knee (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Paradigm Biopharmaceuticals: open-pipeline peers nationwide
Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Paradigm Biopharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
- Abcentra · 50% recruiting · 2 trials
Related
What to do with this Paradigm Biopharmaceuticals page
2 registered trials is a research-attention snapshot, not an endorsement of Paradigm Biopharmaceuticals or any single study.
- 1 of Paradigm Biopharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Osteoarthritis, Knee is the condition Paradigm Biopharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Osteoarthritis, Knee trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Paradigm Biopharmaceuticals pipeline card: 2 registered trials from official public datasets.Report a data error.